alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
### IN THE COURT OF APPEALS OF TENNESSEE AT NASHVILLE May 14, 2024 **IN RE RAYDEN R. ET AL. Appeal from the Juvenile Court for Williamson County** 

**No. 39627 Sharon Guffee, Judge** 

**___________________________________ No. M2024** **- 00618** **- COA** **- R3**  **- PT** 

**___________________________________** A mother appeals the termination of her parental rights. Because the mother did not file her notice of appeal within thirty days after entry of the final judgment as required by Tennessee Rule of Appellate Procedure 4(a), we dismiss the appeal.

**Tenn. R. App. P. 3 Appeal as of Right; Appeal Dism issed**  A NDY D. B ENNETT, W. NEAL MCB RAYER, and JEFFREY U SMAN , JJ
. Gregory Wade Dawson, Nashville , Tennessee, for the appellant, Leila N
. Katherine P. Adams , Nashville , Tennessee, for the appellee, Tennessee Department of Children’s Services. Kevin D
. Balkwill , Brentwood, Tennessee, Guardian ad Litem. **MEMORANDUM OPINION** 1 Leila N. (“Mother”) has filed a notice of appeal from a final judgment entered by the Juvenile Court for Williamson County on March 25, 2024 , terminating her parental rights. The guardian ad litem has move d to dismiss the appeal for failure to file a timely notice of appeal. Tennessee Rule of Appellate Procedure 4(a) requires that a notice of appeal be filed with the clerk of the appellate court within thirty days after entry of the judgment appealed. Mother did not file her notice of appeal until April 25 , 2024 , thirty

one days after entry of the judgment. Mother has not filed a response in opposition to the motion to dismiss
.

1 Under Tennessee Court of Appeals Rule 10, a case decided by memorandum opinion shall not be published and shall not be cited or relied on for any reason in any unrelated case.- 2
-

We are reluctant to dismiss an appeal involving the termination of parental rights based solely on counsel ’s filing of the notice of appeal one day late
. However, the time limit for filing a notice of appeal is mandatory and jurisdictional. Albert v. Frye, 145 S.W.3d 526, 528 (Tenn. 2004); Binkley v. Medling, 117 S.W.3d 252, 255 (Tenn. 2003). The failure to file a timely notice of appeal deprives this Court of jurisdiction to hear the matter. Flautt & Mann v. Council of City of Memphis, 285 S.W.3d 856, 869 (Tenn. Ct. App. 2008 )
. While a trial court may, under unusual and compelling circumstances, grant an appellant relief from the failure to file a timely notice of appeal under Tennessee Rule of Civil Procedure 60, such relief must be sought in the trial court. Tenn. R. App. P. 4(a), Advisory Commission Comments; McCracken v. Brentwood United Methodist Church , 958 S.W.2d 792 (Tenn. Ct. App. 1997). This Court can neither waive nor extend the thirty

- day time period. The appeal is hereby dismissed for failure to file a timely notice of appeal. The case is remanded to the trial court for further proceedings consistent with this opinion. The costs are taxed to Leila N. for which execution may issue.
PER CURIAM
§ 529.539 Dexmedetomidine. ( a ) *Specifications.* Each milliliter of gel contains 0.09 milligrams (mg) dexmedetomidine (equivalent to 0.1 mg dexmedetomidine hydrochloride).
( b ) *Sponsor.* See No. 052483 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Amount.* Administer onto the oral mucosa between the dog's cheek and gum at a dose of 125 micrograms per square meter.
( 2 ) *Indications for use.* For the treatment of noise aversion in dogs.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[81 FR 17608, Mar. 30, 2016]
**Exhibit 32**

 

**CERTIFICATIONPURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

 

Pursuant to 18 U.S.C. § 1350,as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, theundersigned officers of Pace Medical, Inc., a Massachusetts corporation(the “Company”) do hereby certify, to the best of such officers’ knowledge andbelief, that:

 

(1) The QuarterlyReport of the Company on Form 10-QSB for the period ending June 30,2005 as filed with the Securities and Exchange Commission on or about the datehereof (the “Report”) fully complies with the requirements of Section 13(a) or15(d) of the Securities Exchange Act of 1934; and

 

(2) The informationcontained in the Report fairly presents, in all material respects, thefinancial condition and results of operations of the Company.

 

 
| Date:  August 12, 2005 | /s/ Steven E. Hanson                   |   |
|----------------------------------|----------------------------------------|--------|
|                             | Steven E. Hanson                       |   |
|                             | President and Chief  Executive Officer |   |
|                             |                                   |   |
|                             |                                   |   |
| Date:  August 12, 2005 | /s/ Ralph E. Hanson                    |   |
|                             | Ralph E. Hanson                        |   |
|                             | Treasurer                              |   |

 

----
EXHIBIT 32
----------




                           CERTIFICATIONS OF
          CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
                  PURSUANT TO 18 U.S.C. SECTION 1350,
              AS ADOPTED PURSUANT TO SECTION 906 OF THE
                      SARBANES-OXLEY ACT OF 2002
          ---------------------------------------------------



     The following statement is provided by the undersigned to accompany
the Quarterly Report on Form 10-Q for the quarter ended March 31, 2004,
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be
deemed filed pursuant to any provision of the Securities Exchange Act of
1934 or any other securities law:

     Each of the undersigned certifies that the foregoing Report on
Form 10-Q fully complies with the requirements of Section 13(a) of the
Securities Exchange Act of 1934 (15 U.S.C. 78m) and that the information
contained in the Form 10-Q fairly presents, in all material respects, the
financial condition and results of operations of ARVIDA/JMB PARTNERS, L.P.




                                       /s/   Gary Nickele
                                       ------------------------------
                                       Gary Nickele
                                       Chief Executive Officer




                                       /s/   Gailen J. Hull
                                       ------------------------------
                                       Gailen J. Hull
                                       Chief Financial Officer and
                                       Principal Accounting Officer
<PAGE>

                                                                    Exhibit 23.1

                                                                 [ANDERSEN LOGO]

Consent of Independent Public Accountants

As independent public accountants, we hereby consent to the inclusion in this
Form 10-K/A of our report dated March 20, 2001 on the financial statements of
GlycoGenesys, Inc. (formerly SafeScience, Inc.), as of December 31, 1999 and
2000 and for each of the two years in the period ended December 31, 2000, and to
all references to our Firm included in this Form 10-K/A. We also consent to the
incorporation of our report included in this Form 10-K/A into the Company's
previously filed Registration Statements on Forms No. 333-35874, 333-35876,
333-38964, 333-40322, 333-43038, 333-60132, 333-70976, 333-70982, 333-71954 and
333-81208. It should be noted that we have not audited any financial statements
of the Company subsequent to December 31, 2000 or performed any audit procedures
subsequent to the date of the report.

/s/ Arthur Andersen LLP

Boston, Massachusetts
May 24, 2002
Exhibit 10.6


                              GULFWEST ENERGY INC.

                             Directors Compensation


Annual  Retainer  and Meeting  Fees.  Effective  June 1, 2005 each  non-employee
Director  will  receive an annual  retainer  of  $10,000  payable  quarterly  in
arrears,  and board meeting  attendance fees in the amount of $2,000 per meeting
if attending in person or $1,000 per meeting if  participating by phone (maximum
annual amount of $8,000).  Committee  members will also receive meeting fees for
committee meetings to the extent that those meetings are held on days other than
scheduled meetings of the entire Board. The Chairman of the Audit Committee will
receive an additional  annual  retainer in the amount of $5,000 and the Chairman
of the  Compensation  Committee will receive an annual retainer in the amount of
$2,500.  Both the Audit Committee and Compensation  Committee  retainers will be
paid  semi-annually.  No Director  who is an  employee  of the  Company  will be
compensated  for service as a member of the Board of Directors or any  committee
of the Board of Directors.

Share Awards.  Effective June 1, 2005 each non-employee Director will receive an
initial grant of $15,000 of restricted  stock (based on the fair market value of
the  stock  on the  date  of  grant)  with a two  year  vesting  schedule.  Upon
re-election,  each non-employee Director will receive an annual grant of $10,000
of  restricted  stock with a one year  vesting  schedule.  Annual  share  awards
received by  non-employee  Directors are in addition to the Annual  Retainer and
Meeting Fees discussed above.

Expenses.  Each  member of the Board of  Directors  will be  reimbursed  for all
direct  expenses  incurred in the  performance  of his/her duties as a Director,
including reasonable travel expenses incurred in attending meetings of the board
or its committees.


<PAGE>


                              GULFWEST ENERGY INC.

                        Summary of Director Compensation
                        --------------------------------

     o    Annual Retainer of $10,000 payable quarterly

     o    Audit Committee Chairman Retainer of $5,000 payable semi-annually

     o    Compensation   Committee   Chairman   Retainer   of   $2,500   payable
          semi-annually

     o    Board  Meeting  Attendance  Fees of $2,000 per  meeting if attended in
          person,   $1,000  if   participating  by  phone  ($8,000  maximum  per
          individual)

     o    Initial grant of $15,000 Restricted Stock with two year vested

     o    Subject to re-election,  annual grant of $10,000 Restricted Stock with
          one year vested

     o    Payment of reasonable  travel  expenses  associated with Board Meeting
          attendance
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 764 Introduced in House (IH)]

<DOC>

118th CONGRESS
  1st Session
                                H. R. 764

    To require the Secretary of the Interior to reissue regulations 
   removing the gray wolf from the list of endangered and threatened 
           wildlife under the Endangered Species Act of 1973.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                            February 2, 2023

  Mrs. Boebert (for herself, Mr. Tiffany, Mr. Bergman, Mr. Biggs, Mr. 
Gallagher, Mr. LaMalfa, Mr. Moylan, Mr. Nehls, Mr. Newhouse, Mr. Ogles, 
  Mr. Perry, Mr. Rosendale, Mr. Stauber, Mr. Zinke, Mr. Grothman, Mr. 
   Gosar, Mr. Crane, Mr. Van Orden, Mr. Steil, Mr. Fitzgerald, Mrs. 
Fischbach, Mr. Buck, and Mr. Moolenaar) introduced the following bill; 
        which was referred to the Committee on Natural Resources

_______________________________________________________________________

                                 A BILL

 
    To require the Secretary of the Interior to reissue regulations 
   removing the gray wolf from the list of endangered and threatened 
           wildlife under the Endangered Species Act of 1973.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Trust the Science Act''.

SEC. 2. REMOVING THE GRAY WOLF FROM THE LIST OF ENDANGERED AND 
              THREATENED WILDLIFE.

    Not later than 60 days after the date of enactment of this section, 
the Secretary of the Interior shall reissue the final rule entitled 
``Endangered and Threatened Wildlife and Plants; Removing the Gray Wolf 
(Canis lupus) From the List of Endangered and Threatened Wildlife'' and 
published on November 3, 2020 (85 Fed. Reg. 69778).

SEC. 3. NO JUDICIAL REVIEW.

    Reissuance of the final rule under section 2 shall not be subject 
to judicial review.
                                 <all>
```
§ 801.63 Medical devices; warning statements for devices containing or manufactured with chlorofluorocarbons and other class I ozone-depleting substances. ( a ) All over-the-counter devices containing or manufactured with chlorofluorocarbons, halons, carbon tetrachloride, methyl chloride, or any other class I substance designated by the Environmental Protection Agency (EPA) shall carry one of the following warnings: ( 1 ) The EPA warning statement: Warning: Contains [or Manufactured with, if applicable] [*insert name of substance*], a substance which harms public health and environment by destroying ozone in the upper atmosphere.
( 2 ) The alternative statement: Note:
The indented statement below is required by the Federal government's Clean Air Act for all products containing or manufactured with chlorofluorocarbons (CFC's) [or other class I substance, if applicable]: Warning: Contains [or Manufactured with, if applicable] [*insert name of substance*], a substance which harms public health and environment by destroying ozone in the upper atmosphere. CONSULT WITH YOUR PHYSICIAN, HEALTH PROFESSIONAL, OR SUPPLIER IF YOU HAVE ANY QUESTION ABOUT THE USE OF THIS PRODUCT.
( b ) The warning statement shall be clearly legible and conspicuous on the product, its immediate container, its outer packaging, or other labeling in accordance with the requirements of 40 CFR part 82 and appear with such prominence and conspicuousness as to render it likely to be read and understood by consumers under normal conditions of purchase. This provision does not replace or relieve a person from any requirements imposed under 40 CFR part 82.
[61 FR 20101, May 3, 1996]
**MEMORANDUM**

**DATE:** January

30, 2012 **SUBJECT:** Telephone Conference Call with Office of Management and Budget (OMB) on

January 27, 2012 **FROM:** EPA OAQPS **TO:** Secondary Aluminum Production Risk and Technology Review Docket (EPA EPA - HQ - OAR- 2010 - 0544 ) A telephone conference call was held on January 27, 2012 , to discus s OMB comments on proposed changes to the Secondary Aluminum Production NESHAP related to the Risk and Technology

Review for this source category . OMB requested that: a footnote be added to the preamble describing how facilities were selected to receive the nine - company testing ICR; the word “multiplication” be replaced with “default” to describe risk associated with short- term acute exposures; the first sentence of the cost impacts discussion be deleted; and the paragraph on economic impacts be revised consistent with that from the primary aluminum NESHAP rulemaking preamble.
Exhibit








           Exhibit 10.3


Regulus Therapeutics Inc.


Paul C. Grint, M.D. Yearly Discretionary Base Salary Increase


The Board of Directors (the “Board”) of Regulus Therapeutics Inc., upon the recommendation of the Compensation Committee of the Board, approved the increase of Dr. Grint’s annual base salary to $545,900, effective January 1, 2017.
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                                          <C>
<PERIOD-TYPE>                                3-MOS
<FISCAL-YEAR-END>                            MAY-31-1999
<PERIOD-END>                                 AUG-29-1998
<CASH>                                          16,550
<SECURITIES>                                         0
<RECEIVABLES>                                  852,274
<ALLOWANCES>                                         0
<INVENTORY>                                    837,659
<CURRENT-ASSETS>                             1,850,688
<PP&E>                                       3,463,588
<DEPRECIATION>                                (190,130)
<TOTAL-ASSETS>                               5,371,299
<CURRENT-LIABILITIES>                        4,812,653
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        15,433
<OTHER-SE>                                   2,902,110
<TOTAL-LIABILITY-AND-EQUITY>                 5,371,299
<SALES>                                      3,404,428
<TOTAL-REVENUES>                             3,404,428
<CGS>                                        2,682,393
<TOTAL-COSTS>                                3,646,604
<OTHER-EXPENSES>                               (34,513)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              45,238
<INCOME-PRETAX>                               (252,901)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                           (252,901)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (252,901)
<EPS-PRIMARY>                                    (0.16)
<EPS-DILUTED>                                    (0.16)
        

</TABLE>
§ 573.450 Fermented ammoniated condensed whey. ( a ) *Identity.* The product is produced by the *Lactobacillus delbrueckii* fermentation of whey with the addition of ammonia.
( b ) *Specifications.* The product contains 35 to 55 percent crude protein and not more than 42 percent equivalent crude protein from nonprotein nitrogen sources.
( c ) *Uses.* The product is used as a source of protein and nonprotein nitrogen for cattle.
( d ) *Limitations.* ( 1 ) Store in a closed vented tank equipped for agitation. Agitate 5 minutes before using. Do not store at temperature above 110 °F (43 °C).
( 2 ) The maximum level of use of fermented ammoniated condensed whey and equivalent crude protein from all other added forms of nonprotein nitrogen shall not exceed 30 percent of the dietary crude protein.
( 3 ) The additive may be used as follows: ( i ) Mixed with grain, roughage, or grain and roughage prior to feeding.
( ii ) As a component of free-choice liquid feeds, used to supplement the diets of cattle fed other sources of nutrients, fermented ammoniated condensed whey shall not exceed 80 percent of the free-choice liquid feed.
( e ) *Labeling.* The label shall bear, in addition to other information required by the act: ( 1 ) The name of the additive.
( 2 ) The maximum percentage of equivalent crude protein from nonprotein nitrogen.
( 3 ) Adequate directions for use in accordance with the provisions in paragraph (d) of this section.
[43 FR 33708, July 1, 1978, as amended at 46 FR 49115, Oct. 6, 1981; 89 FR 67856, Aug. 22, 2024]
§ 821.55 Confidentiality. ( a ) Any patient receiving a device subject to tracking requirements under this part may refuse to release, or refuse permission to release, the patient's name, address, telephone number, and social security number, or other identifying information for the purpose of tracking.
( b ) Records and other information submitted to FDA under this part shall be protected from public disclosure to the extent permitted under part 20 of this chapter, and in accordance with § 20.63 of this chapter, information contained in such records that would identify patient or research subjects shall not be available for public disclosure except as provided in those parts.
( c ) Patient names or other identifiers may be disclosed to a manufacturer or other person subject to this part or to a physician when the health or safety of the patient requires that such persons have access to the information. Such notification will be pursuant to agreement that the record or information will not be further disclosed except as the health aspects of the patient requires. Such notification does not constitute public disclosure and will not trigger the availability of the same information to the public generally.
[58 FR 43447, Aug. 16, 1993, as amended at 67 FR 5951, Feb. 8, 2002]
# C_2016111EN.01002201.xml

| 29.3.2016 | EN | Official Journal of the European Union | C 111/22 |
| --- | --- | --- | --- |

29.3.2016

EN

Official Journal of the European Union

C 111/22

---

Judgment of the General Court of 18 February 2016 — Penny-Markt v OHIM — Boquoi Handels (B! O)

(Case T-364/14) (1)

1

((Community trade mark - Invalidity proceedings - Community figurative mark B! O - Earlier Community word mark bo - Relative ground for refusal - Article 53(1)(a) and Article 8(1)(b) of Regulation (EC) No 207/2009))

(2016/C 111/26)

Language of the case: German

Parties

Parties

Applicant: Penny-Markt GmbH (Cologne, Germany) (represented by: M. Kinkeldey, S. Brandstätter and A. Wagner, lawyers)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: initially, A. Pohlmann, subsequently, S. Hanne, and lastly, A. Schifko, acting as Agents)

Defendant:

Other party to the proceedings before the Board of Appeal of OHIM, intervener before the General Court: Boquoi Handels OHG (Straelen, Germany) (represented by: P. Mels, lawyer)

Other party to the proceedings before the Board of Appeal of OHIM, intervener before the General Court:

Re:

Re:

Action brought against the decision of the Fourth Board of Appeal of OHIM of 21 March 2014 (R 1201/2013-4), relating to invalidity proceedings between Boquoi Handels OHG and Penny-Markt GmbH

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | dismisses the action; |
| --- | --- |

1.

dismisses the action;

| 2. | orders Penny-Markt GmbH to pay the costs. |
| --- | --- |

2.

orders Penny-Markt GmbH to pay the costs.

---

(1)  OJ C 261, 11.8.2014.

1

---
§ 522.1700 Pentobarbital and phenytoin. ( a ) *Specifications.* Each milliliter (mL) of solution contains 390 milligrams (mg) pentobarbital sodium and 50 mg phenytoin sodium.
( b ) *Sponsors.* See Nos. 000061, 051311, 054925, and 086119 in § 510.600(c) of this chapter.
( c ) *Special considerations.* Product labeling shall bear the following warning statements: “ENVIRONMENTAL HAZARD: This product is toxic to wildlife. Birds and mammals feeding on treated animals may be killed. Euthanized animals must be properly disposed of by deep burial, incineration, or other method in compliance with State and local laws, to prevent consumption of carcass material by scavenging wildlife.”
( d ) *Conditions of use in dogs* — ( 1 ) *Amount.* Administer 1 mL per 10 pounds of body weight as a single, bolus intravenous or intracardiac injection.
( 2 ) *Indications for use.* For humane, painless, and rapid euthanasia.
( 3 ) *Limitations.* Do not use in animals intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[85 FR 18120, Apr. 1, 2020, as amended at 85 FR 45308, July 28, 2020. Redesignated at 86 FR 61685, Nov. 8, 2021; 88 FR 84701, Dec. 6, 2023]